ARTHEx Biotech — Series B · €42M

Valencia-based clinical-stage biotech ARTHEx closed a €42M Series B led by Columbus Venture Partners to take ATX-01, an antimiR targeting microRNA-23b, into a Phase I/IIa trial for Myotonic Dystrophy Type 1. New investors EIC, Hadean Ventures and Sound Bioventures joined existing backers Invivo Capital, AdBio Partners and CDTI-Innvierte.

LeadColumbus Venture Partners RoundSeries B Announced3 May 2023 CityValencia SectorHealthtech & Bio · Biotech Source P E

Something wrong? Suggest a correction →